1
Clinical Trials associated with Malaria Vaccine P27A(Centre Hospitalier Universitaire Vaudois)Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A With Alhydrogel® Or GLA-SE As Adjuvant: A Staggered, Antigen And Adjuvant Dose-Finding, Randomized, Multi-Centre Phase Ia/Ib Trial
P27A study is designed as a randomized phase Ia/Ib trial to evaluate the safety and immunogenicity of the blood stage candidate vaccine P27A against P. falciparum - P27A antigen and associated adjuvant (Alhydrogel or GLA-SE) - in malaria non exposed European volunteers(Switzerland; phase Ia) and malaria exposed African volunteers (Tanzania; phase Ib).
100 Clinical Results associated with Malaria Vaccine P27A(Centre Hospitalier Universitaire Vaudois)
100 Translational Medicine associated with Malaria Vaccine P27A(Centre Hospitalier Universitaire Vaudois)
100 Patents (Medical) associated with Malaria Vaccine P27A(Centre Hospitalier Universitaire Vaudois)
100 Deals associated with Malaria Vaccine P27A(Centre Hospitalier Universitaire Vaudois)